The past decade has seen significant advances in the understanding of hidradenitis suppurativa pathogenesis, informing research into novel treatment approaches, such as biologics, and expanded indications for existing pharmacologic agents. Ali Alikhan, MD reviews the evolving landscape in HS and revolutions in treatment approaches.
In the second video in a series, Steven Cohen, MD talks about standard and new treatments for hidradenitis suppurativa. He talks to host Adam Friedman, MD about optimized regimens and long-term patient support.
Evidence shows that infliximab, with its weight-based dosing, can be effective for hidradenitis suppurative. Steven Cohen, MD discusses the data and practical considerations with host Adam Friedman, MD.
With a surge in new research over the last decade, dermatologists are learning more about Hidradenitis Suppurativa, comorbidities, and quality of life impact. In the first of a series, Steven Cohen, MD discusses HS with host Adam Friedman, MD.
DermWireTV: Practices Reopen; Prescriber's Choice Expands; Sun Takes on Acne
FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Old
Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes So
DermWire Exclusive: Inside the COVID-19 Outbreak in Italy with Dr. Sebastiano Recalcati
Lessons from Italy: Understanding and Recognizing Potential Skin Manifestations in COVID-19
Special Report: COVID-19: Surgeons Support Front Lines, How to Cope
COVID-19 Update: AAD, Others React to Potential Shortage of Malaria and Arthritis Drugs
Nation's Largest Nurses Union to Congress: Ensure Standards for Healthcare Workers to Avoid COVID-19
International Psoriasis Council Offers Guidance on Managing COVID-19 in People with Psoriasis
First Patient Enrolled in Avita Medical’s Pivotal Study Evaluating Recell System for Soft Tissue Reconstruction
Ortho Dermatologics Launches Telemedicine on Dermatology.com, US Cash-Pay Prescription Program